<DOC>
	<DOCNO>NCT00425373</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy fix combination valsartan ( 40 mg 80 mg ) amlodipine ( 2.5 mg 5 mg ) , valsartan amlodipine alone , placebo reduce blood pressure . The study investigate dose response relationship combination , monotherapies , placebo .</brief_summary>
	<brief_title>Efficacy Safety Valsartan Amlodipine Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion criterion Patients essential hypertension measure electronic hemodynamometer . Patients must satisfy follow criterion . 1 . MSDBP &lt; 110 mmHg MSSBP &lt; 180 mmHg Visit 1 2 . MSDBP ≥ 90 mmHg &lt; 110 mmHg MSSBP &lt; 180 mmHg Visit 2 3 . MSDBP ≥ 95 mmHg &lt; 110 mmHg MSSBP &lt; 180 mmHg Visit 3 4 . The absolute difference MSDBP Visit 2 3 ≤ 10 mmHg Male female outpatient . Aged = &gt; 20 = &lt; 80 year ( time signing informed consent ) . Patients write informed consent participate study . Exclusion criterion Pregnant woman , nursing ( lactate ) mother , woman suspect pregnant , woman wish pregnant study , woman childbearing potential . Patients secondary hypertension suspect secondary hypertension . Patients history malignant hypertension . Patients inability completely discontinue prior antihypertensive medication safely period 12 week require protocol . Patients history follow disease sign : Cardiac disease , renal disease , cerebrovascular disorder Patients clinically significant allergy ( asthma pharmacotherapy , multidrug allergy , druginduced foodinduced anaphylactic reaction ) . Patients hypersensitive AII receptor antagonist , calcium channel blocker dihydropyridine derivative . Known moderate malignant retinopathy . Patients history pancreatitis . Patients pancreatic injury , evidence impair pancreatic function/injury within 12 month Visit 1 . Patients surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug . Patients volume depletion base investigator 's subinvestigator 's clinical judgment use vital sign , skin turgor , moistness mucous membrane laboratory value . Patients find low Na K ( Na &lt; 130 mEq/L , K &lt; 3.3mEq/L ) high parameter ( Na ≥ 152 mEq/L , K ≥ 5.2 mEq/L ) laboratory test Visit 1 . Patients type I diabetes mellitus treatment insulin , patient type II diabetes poor glucose control define glycosylated hemoglobin ( HbA1c ) &gt; 8.0 % Visit 1 . Patients history malignant tumor include leukemia lymphoma , treat untreated , within past 5 year Visit 1 whether evidence local recurrence metastasis ( except localize basal cell carcinoma skin ) . Patients severe , lifethreatening disease within past 5 year . Patients history autoimmune diseases rheumatoid arthritis systemic lupus erythematosus . Any surgical medical condition , opinion investigator subinvestigator , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . Patients history drug alcohol abuse within last 2 year Visit 1 . Patients receive investigational product within 12 week Visit 1 . Any chronic inflammatory condition need chronic antiinflammatory drug therapy . Persons directly involve execution study . Patients consider unlikely comply requirement specify protocol investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Hypertension , Valsartan , Amlodipine , high blood pressure</keyword>
</DOC>